IPCA Laboratories · NSE: IPCALAB · BSE: 524494

Q4 FY25 results · Jan–Mar 2025

IPCA Laboratories reported revenue from operations of ₹2,246.69 crore (up 10.5% from Q4 FY24) and net profit of ₹63.99 crore (up 4711.3% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY25	Q4 FY24	YoY	Q3 FY25	QoQ
Revenue from operations	2,246.69	2,033.01	+10.5%	2,245.37	+0.1%
Other income	25.82	18.92	+36.5%	20.11	+28.4%
Total income	2,272.51	2,051.93	+10.7%	2,265.48	+0.3%
Profit before share of associates & JVs and tax	128.00	76.60	+67.1%	367.92	−65.2%
Share of profit/(loss) of associates & JVs	(1.79)	(1.58)		(0.97)
Net profit for the period	63.99	1.33	48x	276.36	−76.8%
Attributable to shareholders of the company	67.82	59.59	+13.8%	248.14	−72.7%
EPS, basic (₹)	2.67	2.35	+13.7%	9.78	−72.7%
Net margin (%)	2.8	0.1		12.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY25	Q4 FY24	YoY	Q3 FY25	QoQ
Revenue from operations	1,638.44	1,510.62	+8.5%	1,662.68	−1.5%
Other income	21.49	15.10	+42.3%	17.41	+23.4%
Total income	1,659.93	1,525.72	+8.8%	1,680.09	−1.2%
Profit before tax	17.15	127.30	−86.5%	355.52	−95.2%
Net profit for the period	(65.05)	64.76	Turned loss	267.56	Turned loss
EPS, basic (₹)	(2.56)	2.55	Turned loss	10.55	Turned loss
Net margin (%)	-4.0	4.3		16.1

Consolidated

Filed with BSE: 29 May 2025, 20:09 IST
Board meeting: 29 May 2025
Period: 01 Jan 2025 to 31 Mar 2025
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 29 May 2025, 20:09 IST
Board meeting: 29 May 2025
Period: 01 Jan 2025 to 31 Mar 2025
Review status: Audited
Source: XBRL filing on BSE